Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $39.5 million.

  • Mirum Pharmaceuticals' Free Cash Flow rose 93849.59% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.3 million, marking a year-over-year increase of 211628.75%. This contributed to the annual value of $9.3 million for FY2024, which is 11313.39% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Free Cash Flow stood at $39.5 million, which was up 93849.59% from $11.9 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Free Cash Flow peaked at $39.5 million during Q3 2025, and registered a low of -$40.2 million during Q2 2021.
  • Moreover, its 5-year median value for Free Cash Flow was -$18.2 million (2023), whereas its average is -$14.0 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 13581.28% in 2021, then surged by 93849.59% in 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Free Cash Flow (Quarter) stood at -$33.2 million in 2021, then dropped by 4.11% to -$34.5 million in 2022, then surged by 51.85% to -$16.6 million in 2023, then surged by 69.38% to -$5.1 million in 2024, then skyrocketed by 876.22% to $39.5 million in 2025.
  • Its Free Cash Flow was $39.5 million in Q3 2025, compared to $11.9 million in Q2 2025 and -$2.0 million in Q1 2025.